Ratings Summary for HUMIRA

Overall Patient opinion of HUMIRA: 3.1 (satisfied)

(based on 750 reviews ) (updated May 6, 2025)

Ratings by Age Group for HUMIRA
Rating Scale from 1 (poor) to 5 (excellent)

Patient Age Group	Number of Reviews	Average Rating
Pediatric (Under 18)	18	2.6
Age 18 to 24	45	3.5
Age 25 to 34	134	3.5
Age 35 to 44	177	3.0
Age 45 to 54	182	3.0
Age 55 to 64	131	3.0
Age 65 to 74	48	3.0
Age 75 and up	1	3

Ratings by Sex for HUMIRA
Rating Scale from 1 (poor) to 5 (excellent)

Patient Sex	Number of Reviews	Average Rating
Male	242	3.25206611570248
Female	499	3.06813627254509
Not Specified	9	2.88888888888889

Would you like to find reviews for HUMIRA taken for a specific reason or resulting in a specific side effect?

Filter Results for HUMIRA

Patient Type:	Any Male Female
Reason(s):
Side Effect(s):
Satisfaction:	1 2 3 4 5

FDA Drug Safety Information for HUMIRA

Check here for Ask a Patient's Adverse Event Summary for HUMIRA based on cases submitted to the FDA. Includes top reasons for taking, adverse events, and major outcomes reported.

HUMIRA (ADALIMUMAB): Adalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, ankylosing spondylitis). This medication is also used to treat certain skin disorders (such as plaque-type psoriasis, hidradenitis suppurativa). It works by blocking a protein (tumor necrosis factor or TNF) found in the body's immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis. Adalimumab belongs to a class of drugs known as TNF blockers. By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function. Adalimumab is also used to treat certain bowel conditions (Crohn's disease, ulcerative colitis) and a certain eye disease (uveitis). FDA Approval Date: (Sources: U.S. Centers for Medicare Services, FDA)